
PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC
PARP inhibitor and androgen receptor pathway inhibitor (ARPI) combination therapies have shown promise in patients with metastatic castration-resistant prostate cancer (mCRPC) who have BRCA mutations and homologous recombination repair (HRR) gene …